Immutep receives EUR 1.36 million French R&D tax incentive
IMMP•Immutep received EUR 1.36 million (approximately AUD 2.16 million) under France’s R&D tax incentive for eligible 2025 research.
1. Funding supports research
The non-dilutive funding will support current R&D on Immutep’s product candidates eftilagimod alfa and IMP761.
